Bridging the gap between innovation and capital
Cystic Fibrosis Foundation: IC RARE
Focus on gene editing/insertion, gene transfer, and gene delivery technologies.
Program
The Cystic Fibrosis Foundation (CFF) is a highly active, mission-driven, venture capital investor. They have a multibillion dollar endowment and a $600M+ commitment to venture investments over the next several years. They support a wide array of biotech companies. In particular, they have a strategic focus on gene editing/insertion, gene transfer, and gene delivery technologies. They often work to identify platform technologies that, though not currently working on cystic fibrosis, may be applicable to specific challenges in the treatment of CF. They are flexible partners and can invest in biotech companies through a wide range of market-standard investment vehicles.
Event
LaunchBio, Browne Consulting, and Silicon Valley Bank, a division of First Citizens Bank, are pleased to announce their next Investor Connect virtual event with The Cystic Fibrosis Foundation.
In addition to deploying capital across all development stages, they avail a variety of resources to assist portfolio companies including:
- A 45 FTE research lab
- Best in class assays and training
- Biobank of cell lines & tissue types
- Patient registry
- Clinical trial development network of 100+ sites
- Industry leading KOLs/SMEs
Applications will be selected based on meeting the following criteria:
Geography
Most of the current investments in EU and US, but open to invest globally
Areas of Focus
GENETIC MEDICINES
- Protein Restoration – Improved RNA-based approaches, redosable therapies targeting the lung, and longer-duration treatments
- Gene Delivery – Organ- and cell-specific targeting (lung-focused delivery, redosing capabilities)
- Gene Editing – Functional gene insertions to restore gene function, targeted edits for precision treatments
INFECTIOUS DISEASE
- Pseudomonas Aeruginosa Infections – Advanced treatments for chronic infections
- Other Gram Negative Infections – Targeting Burkholderia cenocepacia, A. xylosoxidans, and S. maltophilia
- Detection and Diagnostics of Pulmonary Infections – Faster and precise non-sputum-based detection methods
- NTM-PD, Staph and Fungal Pulmonary Infections – Innovative therapies for common CF-associated pathogens
Target organ/system
Gastrointestinal Tract, Lungs/Respiratory System, Pancreas
Stage
Stage-agnostic, CF Foundation invests in Seed through Pre-IPO
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Browne Consulting and Silicon Valley Bank, a division of First Citizens Bank.